Proheb+
Advanced Microbial Preparation
Advanced microbial preparation jointly developed by the University of Hong Kong and the University of Eastern Finland, effectively regulating liver function and improving gut health.
About Proheb
Focusing on microbial preparation research and development, committed to improving liver and gut health
Our Mission
The Proheb team consists of leading scientists from the University of Hong Kong and the University of Eastern Finland, dedicated to improving liver and gut health through innovative microbial preparation technology. Under the leadership of Dr. Hani, Vice Dean of the School of Biological Sciences at HKU, our R&D team has developed the world's only innovative drug in the microbial field that can prevent and treat liver diseases such as HCC while effectively improving gut microbiota balance.
Our breakthrough research results have been published in PNAS (Proceedings of the National Academy of Sciences), with experiments proving that Prohep microbial preparation can effectively inhibit hepatocellular carcinoma (HCC) tumor growth and significantly improve gut microbiota balance. This technology has received patent certification in the United States, China, and Europe, bringing revolutionary treatment solutions for patients with liver diseases and gut health issues.
Years of Microbial Preparation Research
International Healthcare Academic Awards
Healthcare R&D Team Ranking
Product Efficacy & Indications
Proheb microbial preparation provides professional regulation for various health issues
People with digestive discomfort, frequent constipation, or diarrhea
People with seasonal allergies, rhinitis, or low immunity
People with unstable blood sugar or chronic diseases (such as non-alcoholic fatty liver, type 2 diabetes, and other metabolic disorders)
People seeking healthy weight management
People who frequently stay up late, eat late-night meals, or drink alcohol and need liver protection
Expert Team
Gathering top domestic and international experts to safeguard your health
- Vice Dean of the School of Biotechnology at the University of Hong Kong (Tenured)
- Professor at the University of Eastern Finland Medical School (Tenured)
- Finnish Academy of Sciences Researcher and Academician (Researcher Level)
- Prohep Project R&D Leader, Co-founder of Linjia Pharmaceuticals (Shareholder), Chief Scientist of Linjia Pharmaceuticals
- World-leading figure in the microbial industry, published 210 papers in mainstream scientific and medical journals, Google Scholar with H-index of 47, academic papers cited 10,162 times
- Ranked in the top 2% of global scientists (biomedicine, food science) by Stanford University for 5 consecutive years (2020-2024)
- Published over 200 papers in journals including New England Journal of Medicine, Cell, Nature Science, and Nature Genetics
- Discovered the CDH17 gene at the University of Hong Kong and filed for patent
- Entered the pharmaceutical industry in 2011, joining Roche and Janssen Pharmaceuticals, leading drug development projects in oncology, immunology, and hepatitis
- Graduated from East China University of Science and Technology, 20 years of experience in chemical, food, and pharmaceutical industries
- Former Production Plant Manager at DuPont's Kunshan factory, with rich experience in new product development, production operations management, and quality control
- Participated in the production of Johnson & Johnson's leukemia treatment drug in China
- Finland Factory Director, responsible for Prohep preparation raw material production and process development
- Founder and CEO of Fuko Pharma Oy, a leading Finnish biomanufacturing company
- Assistant Professor of Gut Health and Food Safety, Toxicology at the University of Hong Kong
- Speaker at international conferences including the 15th International Congress of Toxicology (IUTOX) and 2018 Global Challenges in Food, Nutrition and Environment
- Speaker representing Chinese projects at the 2019 BRICS Biotechnology China Summit
Certifications
Multiple authoritative certifications, trustworthy quality
Latest Updates
Stay informed about Proheb's latest research achievements and product information
倍合益生菌Proheb+的核心益生菌配方，Prohep，在改善脂肪肝乃至其进展期——代谢相关脂肪性肝炎（通常由脂肪肝恶化而来，肝脏开始发炎甚至损伤）方面，展现出令人鼓舞的治疗潜力！
5月28日，2025年金砖国家技术转移中心协作会议在昆明启幕。金砖国家技术转移中心协作会议为全球科技合作搭建了桥梁，Proheb+也将持续以创新为核心，深化与国际伙伴的协同研发，推动更多突破性发展惠及全球患者。